Global Blood Therapeutics, Inc. (GBT), is a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. More »

Featured News

Recent News

06/14/19GBT Announces Updated 24-Week Efficacy Data from All Patients Enrolled in Phase 3 HOPE Study Showing Statistically Significant and Sustained Improvements in Hemoglobin with Voxelotor
06/10/19GBT Awards More than $200,000 in Grants to Five Nonprofit Organizations through New ACCEL Program Aimed at Improving Access to Healthcare for People Living with Sickle Cell Disease
06/07/19GBT Announces New Employment Inducement Grants
05/16/19GBT Announces Upcoming Data Presentations at 24th European Hematology Association (EHA) Congress Supporting Voxelotor Sickle Cell Disease Program

More »

Media Resources

Media Contact

Stephanie Yao